How Did GST Affect The Pharmaceutical Industry?
The year 2016-17 has been a significant year for
Indian Economy, as it has witnessed an arsenal of economic reforms that are set
to change the market functionality. Among various others, GST is one reform that
took the entire business fraternity by storm. Especially, the pharmaceutical
industry got a good jolt, as there was a lot of uncertainty surrounding the
impact of GST on it.
The pharmaceutical industry in India is the third largest in the world in terms of volume and
is growing at 13% every year. However, a handful of experts are worried that
with the implementation of GST, the market may get stagnant and cease to grow.
The pharma industry is currently valued at US$ 100 billion and it has 15-18%
hold in the inventory section at any given point of time. It is estimated that
with the new rate after GST, distributors and retailers are about to lose 3-4%
on total inventory. So, experts fear that even a 3-4% loss in the overall value
chain will accumulate a huge loss to the industry. They are hoping that
the government takes care of the issue as a crucial one.
The first and foremost problem the pharmaceutical
industry has faced is the hike in the price of the raw materials. With the
implementation of GST, the pharma companies are bound to pay extra 7%, and
thus, rising the MRP of the medicines. If we talk about the impact of GST on
the end consumer, they experience a total of 4% price hike in the MRP of
medicinal products. So, the government has taken steps to curb it down by
controlling the drug prices and even restricted MRPs of many salts/compounds.
This has led the pharmaceutical companies to incur a loss of 2-3%. So, unlike
other industries, the GST will impact the Drugs Price Control Order in the
pharma industry. The industry has more than 65,000 formulations and thousands
of manufacturers, so the competition is intense in the market. Among all other
industries, it is the only price-controlled industry and hence this peculiar
problem.
Moreover, a lot of policies and schemes of
pharmaceutical companies need to be changed, owing to this tax reform. Pratik
Shah, Partner and Head, Indirect Tax Practice, SKP, said in an interview that
the implementation of GST would impact free drug samples, expired material
return policy and bonus schemes. He also added that pharma companies now have
to rethink of incentives.
Despite these complications, the GST is expected to
help the pharmaceutical industry in
many different ways. An amalgamation of all the taxes into a uniform one will
help the businesses to run smoothly, as it will reduce the surging effect of
diverse taxes, applied to just one product. As experts are saying that it would
help the industry in the long run, we need to wait and watch.
Comments
Post a Comment